Inclusion Criteria:

        Subjects must meet the following inclusion criteria:

          -  Ongoing androgen deprivation therapy with a gonadotropin releasing hormone (GnRH)
             analogue, antagonist, or bilateral orchiectomy (i.e., surgical or medical castration);

          -  Serum testosterone level < 1.7 nmol/L (50 ng/dL) at the Screening visit;

          -  Progressive disease at study entry defined as one or more of the following three
             criteria that occurred while the patient was on androgen deprivation;

          -  No prior cytotoxic chemotherapy

          -  Asymptomatic or mildly symptomatic from prostate cancer;

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 as judged by the
             Investigators' clinical assessment;

          -  Estimated life expectancy of ≥ 6 months;

        Exclusion Criteria:

        Subjects must NOT meet any of the following exclusion criteria:

          -  Severe concurrent disease, infection, or co-morbidity that, in the judgment of the
             investigator, would make the patient inappropriate for enrollment;

          -  Known or suspected brain metastasis or active leptomeningeal disease;

          -  Regular daily use of opiate analgesics for pain from prostate cancer within four weeks
             of enrollment (Day 1 visit);

          -  Absolute neutrophil count < 1,500/µL, platelet count < 100,000/µL, and hemoglobin <
             5.6 mmol/L (9 g/dL) at the Screening visit;

          -  Total bilirubin, alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >
             2.5 times the upper limit of normal at the Screening visit;

          -  Creatinine > 177 µmol/L (2 mg/dL) at the Screening visit;

          -  Albumin < 30 g/L (3.0 g/dL) at the Screening visit;

          -  Prior use, or participation in a clinical trial, of an investigational agent that
             blocks androgen synthesis (e.g., abiraterone, galeterone, seviteronel) or blocks the
             androgen receptor (e.g., apalutamide, duralutamide, enzalutamide, proxalutamide);

          -  Participation in a previous clinical trial of HC-1119;

          -  Radiation therapy for treatment of the primary tumor within three weeks of enrollment

          -  Radionuclide therapy for treatment of metastasis;